Mounjaro in English: Understanding the UK's Licensed Tirzepatide Treatment

Where the evidence starts: what the SURMOUNT trials found

The strongest place to begin is the data. SURMOUNT-1, published in the New England Journal of Medicine, randomised 2,539 adults with obesity (without type 2 diabetes) and followed them for 72 weeks. At the 15 mg maintenance dose, participants lost an average of around 20–21% of their starting body weight. That figure comes from a rigorously controlled trial, not from patient testimonials or marketing, a distinction worth holding onto when you read headlines about weight-loss treatments.

One misconception that comes up regularly: people sometimes assume higher weight loss figures mean faster results in the early weeks. The first four weeks at 2.5 mg are a settling-in period designed to reduce gastrointestinal side effects, not to produce dramatic results immediately. The therapeutic work happens as doses increase under prescriber guidance.

A head-to-head comparison against semaglutide 2.4 mg (Wegovy) was published in 2025 (the SURMOUNT-5 trial) and tirzepatide produced greater average weight reduction over 72 weeks. NICE cited this and related indirect comparisons in its appraisal of tirzepatide (TA1026). These are the foundations on which UK licensing and clinical recommendations are built.

How the dual-pathway mechanism differs from earlier GLP-1 medicines

Tirzepatide acts on two receptors: GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). Both are gut hormones involved in appetite regulation, satiety signalling, and blood-glucose control. Earlier medicines in this class (including semaglutide) target GLP-1 alone. The addition of the GIP pathway is what makes tirzepatide the only dual agonist of its kind licensed in the UK for weight management.

In practical terms, both pathways slow gastric emptying and reduce appetite, which is why most people eat noticeably less during treatment. The NHS medicines page for tirzepatide explains this mechanism in patient-friendly language and covers common questions about how to use the KwikPen, injection sites, and what to expect in the first weeks.

The six licensed UK strengths run from 2.5 mg through to 15 mg. Each pen contains four weeks of doses. Injection sites (abdomen, thigh, upper arm) should be rotated. Storage is refrigerated at 2–8°C; for any specific room-temperature guidance, the Patient Information Leaflet that comes with your pen is the definitive reference.

UK eligibility and the private versus NHS route

The licensed UK criteria for Mounjaro cover adults with a BMI of 30 or above, or 27 or above if at least one weight-related condition is present, for example, high blood pressure, type 2 diabetes, dyslipidaemia, or obstructive sleep apnoea. BMI thresholds sit 2.5 kg/m² lower for people from South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds under UK clinical guidance. Meeting the BMI number does not itself guarantee a prescription; a prescriber assesses the full clinical picture, including any conditions that may affect suitability, so if you are wondering how something like a history of shingles fits into that picture, our guide to Mounjaro and shingles covers what prescribers consider.

NICE recommended tirzepatide on the NHS (TA1026, updated September 2025) for a phased rollout based on BMI and comorbidity thresholds. The NHS route is real but access is currently limited and criteria are strict. For people who don't meet the current NHS thresholds, or who prefer not to wait, a regulated UK online pharmacy offering private treatment is the alternative worth understanding. If you want to explore what that route looks like in practice, the overview of Mounjaro in the UK covers the access landscape in more detail, and the rules around prescribing and dispensing explains what a legitimate service is required to do.

For context on the cost side of private treatment, the Mounjaro pricing guide sets out how private market prices have moved since Eli Lilly adjusted its UK list price in September 2025, and what a transparent, all-inclusive price should cover.

Accessing Mounjaro through a regulated UK pharmacy

Mounjaro is a Prescription-Only Medicine under UK law. The only legal route to it is a prescription issued by a qualified prescriber following a proper clinical assessment, identity verified, weight verified, medical history reviewed. That applies whether the prescription comes from your GP, a specialist, or a GPhC-registered online pharmacy.

At nume, every consultation is read the same day by a GPhC-registered Independent Prescriber, a real clinician, not a decision algorithm. Our pharmacy's registration (9012878) is publicly verifiable at the GPhC register. Orders placed before 12pm on a working day are dispatched the same day once clinically approved and delivered free the next working day via DPD, in plain packaging. If you would like a thorough introduction to how the treatment works before starting, our complete guide to Mounjaro brings together the clinical detail, eligibility information, and practical advice in one place. The guide to buying Mounjaro online safely walks through what to check before placing an order with any provider.

Side effects are mostly gastrointestinal (nausea, loose stools, constipation, indigestion) most noticeable in the first weeks or after a dose increase, and they tend to settle. Severe or persistent stomach pain that radiates to the back needs prompt medical attention; the MHRA's Yellow Card scheme is the right place to report any suspected side effect. Our prescribers are available seven days a week if questions come up during treatment.

If you'd like a clinician to assess whether Mounjaro is suitable for you, check your eligibility with a free consultation.